

2008 NYC R&D Funding Conference  
What is NYC Doing for your Company?



# New York City Investment Fund Overview

**David C. Bowie**  
Senior Associate  
New York City Investment Fund  
March 18, 2008

# New York City Investment Fund (NYCIF)

- Established in 1996 by its Co-Chairman, Henry R. Kravis, to mobilize the City's business leaders to help build a stronger and more diversified local economy
- Initially capitalized by contributions of \$1 million each from 67 individual and corporate investors. Current capital exceeds \$110 million
  - “Private Fund with a Civic Mission”
- Since 1997, \$87 million invested in 81 projects, including 32 “venture” investments, 38 “social” investments, and 11 “public/private” investments
- Focus on double bottom line — each project must make business sense and offer benefits to the City - not a charity
- NYCIF looks to leverage the expertise, resources and relationships of its investors and is the investment and economic development arm of the Partnership for New York City ([www.nycif.org](http://www.nycif.org))

# NYCIF focuses on three categories of investment activity:

## Venture / Private Equity

- Venture / Private equity deals that are likely to generate solid financial returns
  - NanIRx Therapeutics
  - TAKKLE

## Social

- Investments that support economic development and social investment goals (e.g., nonprofits, social ventures, minority and neighborhood-based enterprises)
  - Applebee's
  - Greenpoint Manufacturing & Design Center

## Public-Private Initiatives

- High impact projects involving public-private partnerships where the Fund can serve as a catalyst
  - Bioscience Initiative
  - Cleantech

# NYCIF's approach to venture investments

- NYCIF will consider investments at any stage of development but typically invest alongside a lead institutional investor
- Investments usually range in size from \$1 million to \$5 million with a minimum investment of \$500K
- NYCIF is a strategic investor and will invest in an amount proportional to the overall round
- Biotechnology investments include:
  - Intra-Cellular Therapies, a biopharmaceutical company focused on the development of drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System
  - NanIRx Therapeutics, an early-stage, pre-clinical bio-pharmaceutical company focused on developing technology to enhance the efficacy of existing monoclonal antibody drugs, as well as immuno-therapeutics targeted at treating breast cancer and other chronic infectious diseases

# Why is developing a commercial bioscience sector a top priority for NYCIF?

- Need to diversify the local economy beyond the volatile financial services industry
- An active bioscience industry will capitalize on and reinforce NYC's academic health care and research institutions that are among the city's largest employers
- Seeking to add commercial component to an already well-established medical research and education sector
- NYC is starting from a position of strength
  - NIH funding in 2006 for NYC: \$1.3 billion (#2 city nationwide)

# Early Stage Investing & Networking

- Allocation of New York State pension fund monies to venture funds for in-state investing
- Alexandria Real Estate and NYCIF are considering the creation of a vehicle to provide early stage companies in NYC with entrepreneurial expertise and seed capital
- Networking Opportunities
  - NY Academy of Sciences entrepreneurship class
  - m2: Molecular Mixers ([www.labtowallstreet.com](http://www.labtowallstreet.com))
  - NYC Bio ([www.nycbio.org](http://www.nycbio.org))
  - Drop Out Club ([www.dropoutclub.org](http://www.dropoutclub.org))
  - Others?

# Contact Information

## **David C. Bowie**

Senior Associate

New York City Investment Fund  
One Battery Park Plaza, 5<sup>th</sup> Floor  
New York, NY 10004

(p) 212-493-7505

Email: [dbowie@nycif.org](mailto:dbowie@nycif.org)

Website: [www.nycbiotech.com](http://www.nycbiotech.com)